

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Patent Examining Operations

Application of

Mark E. Samuels et al.

Serial No.

10/552,158

Art Unit: Unassigned

Filed

11 December 2006

Examiner: Unassigned

For

Juvenile Hemochromatosis Gene (HFE2A), Expression

Products and Uses Thereof

Docket No.

760050-154

25 June 2006

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### **TRANSMITTAL**

Sir:

Applicants herewith file the following:

- 1. Supplemental Information Disclosure Statement (3 sheets);
- 2. Form 1449 (1 sheet) plus copy of 1 patent reference; and
- 3. Self-addressed, Postage-paid Return Postcard.

Applicant believes that no fees are required in filing these papers. The Commission is authorized to charge any fees, or credit any overpayment, to Deposit Acct. No. 03-0678.

IFW

Serial No.: 10/552,158 Docket No. 760050-154

### FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Alan J. Grant , Esq.

Date

Respectfully submitted,

Alan J. Grant, Esq. Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN

5 Becker Farm Road Roseland, NJ 07068 Phone: 973-994-1700

Fax: 973-994-1744



Application of

Mark E. Samuels et al.

Serial No.

10/552,158

Art Unit: Unassigned

Filed

11 December 2006

Examiner: Unassigned

For

Juvenile Hemochromatosis Gene (HFE2A), Expression

Products and Uses Thereof

Docket No.

760050-154

25 June 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449, which may be material to the patentability of the above-identified application. Applicant(s) make no admission that the cited references are prior art or that these references are in fact material to the patentability of the above-entitled application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

\_X\_§1.97(b) This Information Disclosure Statement is filed:

(1) Within three months of the filing date of a national application; OR

Serial No.: 10/552,158 Docket No. 689290-154 Within three months of the date of entry of the national (2) stage of an international application; OR Before the mailing of a first Office Action on the merits. (3) No fee or statement is required. §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either: A Final Action or under 37 CFR §1.113; OR (1)A Notice of Allowance under 37 CFR §1.311; AND (2) is accompanied by either: (check one) The statement as specified in 37 CFR §1.97(e) set out below; OR The fee of \$180.00 under 37 CFR §1.17(p). This Information Disclosure Statement is filed after the mailing date §1.97(d) of either: (1) a Final Action or under 37 CFR §1.113; OR A Notice of Allowance under 37 CFR §1.311; (2)BUT filed on or before payment of the Issue Fee; AND is accompanied by: The statement as specified in 37 CFR §1.97(e) as set forth below; AND Petition is hereby made under 37 CFR §1.97(d) for (2) consideration of this Information Disclosure Statement; AND. The petition fee of \$130.00 set out in 37 CFR §1.17(i). (3) §1.97(e) The undersigned Attorney hereby states that: each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three

Serial No.: 10/552,158 Docket No. 689290-154

months prior to the filing date of the Information Disclosure Statement.

The Examiner is respectfully requested to consider and make of record all of the cited documents.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

## FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

> Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Alan J. Grant, Esq.

Date

Respectfully submitted,

ilan Thront

Alan J. Grant, Esq. Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN 5 Becker Farm Road Roseland, NJ 07068

Phone: 973-994-1700 Fax: 973-994-1744 JUN 2 9 2007 AUG

Serial No.: Atty. Docket: Form PTO-1449 10/552,158 760050-154 INFORMATION DISCLOSURE STATEMENT Applicant: Mark E. Samuels Filing Date: 11 December 2006 Group: U.S. PATENT DOCUMENTS Document Sub-Filing Examiner Class Date Initial Number Date Name Class Αl 20040102376 27 May 2004 Mueller FOREIGN PATENT DOCUMENTS Document Sub-Examiner Country Class Class Translation Initial Number Date 9 May 1996 В1 WO 96/13518 **PCT PCT** C1 WO 00/73801 7 December 2000 DΙ WO 02/074961 26 September 2002 **PCT** OTHER (Including Author, Title, Date, Pertinent Pages, etc.) E1 F1 G1 ΗI 11 J1 K1 Ll MI NI 01 PΙ Q1 RI Date Considered: Examiner: **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

of \_1

Page\_